BGIM
REGN icon

Boussard & Gavaudan Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-560
Closed -$202K – 23
2016
Q1 		$202K Hold
560
– – 0.11% 20
2015
Q4 		$307K Buy
+560
New +$303K 0.38% 14

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boussard & Gavaudan Investment Management's REGN Position: Q2 2016 in Review

Boussard & Gavaudan Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2016, closing a stake of 560 shares — an estimated $202K sold.

Boussard & Gavaudan Investment Management first reported a position in REGN in Q4 2015 and held it in 2 quarters. The position peaked at $307K in Q4 2015. 542 funds tracked by Wall St. Rank hold REGN as of Q2 2016.

  • Boussard & Gavaudan Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 560 Regeneron Pharmaceuticals shares in Q2 2016, an estimated $202K.
  • Boussard & Gavaudan Investment Management first reported a position in Regeneron Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Boussard & Gavaudan Investment Management's Regeneron Pharmaceuticals position peaked at $307K in Q4 2015.
  • 542 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2016.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q2 2016, filed 3 Aug 2016.